Activity of eltrombopag in severe aplastic anemia - Wikidata - awgldk - TriplyDB

Activity of eltrombopag in severe aplastic anemia

Activity of eltrombopag in severe aplastic anemia

http://www.wikidata.org/entity/Q59133385

about

Activity of eltrombopag in severe aplastic anemia

http://www.wikidata.org/entity/Q59133385

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Activity of eltrombopag in severe aplastic anemia

@en

Activity of eltrombopag in severe aplastic anemia

@nl

type

label

Activity of eltrombopag in severe aplastic anemia

@en

Activity of eltrombopag in severe aplastic anemia

@nl

prefLabel

Activity of eltrombopag in severe aplastic anemia

@en

Activity of eltrombopag in severe aplastic anemia

@nl

P1476

Q59133385-65E64386-B560-42C4-B21F-349E1555A3E4

P2093

Q59133385-3254BB23-9EAA-4AB5-AD0B-73AEAFAB4758

P2860

Q59133385-00E1AA7E-7CDC-434C-8A94-3B1856245A1D

Q59133385-020C7BD8-2D2B-4A7B-AFAB-3A68B9920AEE

Q59133385-02B6FF1D-6614-446F-8D63-E94342852A23

Q59133385-09402B85-B21F-42FF-B648-388D63A39A2A

Q59133385-0D8271F4-E603-458E-A3B0-290D425785DC

Q59133385-0DC41597-E9BD-4BBF-987D-AE9624E3B153

Q59133385-0DCE0A32-C412-402B-9D77-1B519B270F83

Q59133385-12B18203-3123-4A5A-A3C5-5A454E4CC435

Q59133385-17E34C48-EB7E-4554-8432-08923917E756

Q59133385-20876516-909E-4F87-8841-69D18B2890F2

P304

Q59133385-9E1BC715-0482-414D-8AFA-211847741189

P31

Q59133385-1DFE3FD1-82ED-4642-B186-09759E965172

P356

Q59133385-19F38223-6E51-4A45-A05D-F4CAAD7B8B0D

P407

Q59133385-519143A0-507A-4AAC-B727-8B3890A22B67

P433

Q59133385-90E51D01-0BF4-4D5E-BBDF-4781E1BA9996

P478

Q59133385-C5D62398-CF58-48B9-A48C-E6CD189D00C8

P577

Q59133385-BB307ACF-A7D2-4596-9D3A-43EFF97F07D7

P698

Q59133385-3256F72D-5731-4385-9923-BDE19E8DB461

P932

Q59133385-4AC63EB4-4E99-45A7-BC5B-95BC2C322BA5

P356

BLOODADVANCES.2018020248

P1476

Activity of eltrombopag in severe aplastic anemia

@en

P2093

Phillip Scheinberg

http://www.w3.org/2001/XMLSchema#string

P2860

How I treat acquired aplastic anemia

Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia

Current concepts in the pathophysiology and treatment of aplastic anemia

c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia

Compound heterozygosity for two different amino-acid substitution mutations in the thrombopoietin receptor (c-mpl gene) in congenital amegakaryocytic thrombocytopenia (CAMT)

Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia.

Hematopoietic growth factors in the treatment of acquired bone marrow failure states.

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.

Thrombopoietin-receptor agonists for primary immune thrombocytopenia.

Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.

P304

3054-3062

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOODADVANCES.2018020248

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30425070

http://www.w3.org/2001/XMLSchema#string

P932

6234374

http://www.w3.org/2001/XMLSchema#string